Tranquilli Financial Advisor LLC increased its stake in Sanofi (NASDAQ:SNY – Free Report) by 4.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,758 shares of the company’s stock after acquiring an additional 350 shares during the period. Tranquilli Financial Advisor LLC’s holdings in Sanofi were worth $486,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Sanofi by 3.8% during the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock worth $579,587,000 after buying an additional 441,637 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after buying an additional 5,091,304 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after buying an additional 1,456,269 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Sanofi by 1.0% during the fourth quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company’s stock worth $177,304,000 after buying an additional 34,660 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Sanofi by 6.9% during the first quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company’s stock worth $181,764,000 after buying an additional 211,641 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.
Sanofi Stock Down 0.6%
Shares of NASDAQ:SNY opened at $47.16 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company has a market cap of $115.79 billion, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The firm has a 50 day simple moving average of $48.67 and a 200 day simple moving average of $51.97.
Analysts Set New Price Targets
A number of analysts recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Sanofi in a report on Tuesday, August 5th. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price for the company. Finally, Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $62.00.
View Our Latest Stock Analysis on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
- Five stocks we like better than Sanofi
- What is a Special Dividend?
- Worried About a Fading Rally? Consider These 3 Dividend Stocks
- CD Calculator: Certificate of Deposit Calculator
- 3 Dividend Stocks Raising Payouts—and Backing It Up With Results
- Overbought Stocks Explained: Should You Trade Them?
- 3 Stocks With Monopoly Power—and Minimal Competition
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.